| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,474 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
108,818 |
249,559 |
426,745 |
912,388 |
| Total Sell Value |
$7,662,485 |
$17,244,968 |
$23,313,629 |
$45,059,685 |
| Total People Sold |
3 |
4 |
5 |
11 |
| Total Sell Transactions |
6 |
17 |
38 |
84 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Robert I |
President & CEO |
• • – |
2022-11-02 |
4 |
OE |
$7.96 |
$80,938 |
D/D |
10,000 |
406,881 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-10-19 |
4 |
AS |
$47.86 |
$478,600 |
D/D |
(10,000) |
406,089 |
|
-11% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-10-19 |
4 |
OE |
$7.96 |
$79,600 |
D/D |
10,000 |
416,089 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-10-13 |
4 |
AS |
$47.28 |
$1,017,135 |
D/D |
(21,513) |
168,346 |
|
-12% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-10-13 |
4 |
OE |
$9.65 |
$207,600 |
D/D |
21,513 |
189,859 |
|
- |
|
| Henderson John T |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$19,984 |
D/D |
391 |
24,440 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$11,244 |
D/D |
220 |
12,796 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-10-03 |
4 |
AS |
$50.40 |
$504,000 |
D/D |
(10,000) |
406,089 |
|
-15% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-10-03 |
4 |
OE |
$7.96 |
$79,600 |
D/D |
10,000 |
416,089 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$5,622 |
D/D |
110 |
11,396 |
|
- |
|
| Bhanji Muna |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$11,244 |
D/D |
220 |
11,031 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$5,622 |
D/D |
110 |
12,280 |
|
- |
|
| Smith Sandford D |
Director |
• • – |
2022-10-03 |
4 |
A |
$51.11 |
$5,622 |
D/D |
110 |
12,280 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-09-19 |
4 |
AS |
$51.42 |
$514,200 |
D/D |
(10,000) |
406,089 |
|
-19% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-09-19 |
4 |
OE |
$7.96 |
$79,600 |
D/D |
10,000 |
416,089 |
|
- |
|
| Henderson John T |
Director |
• • – |
2022-09-12 |
4 |
AS |
$54.94 |
$1,195,548 |
D/D |
(21,759) |
24,049 |
|
-21% |
|
| Henderson John T |
Director |
• • – |
2022-09-12 |
4 |
OE |
$4.02 |
$87,471 |
D/D |
21,759 |
31,308 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-09-08 |
4 |
AS |
$51.88 |
$1,115,420 |
D/D |
(21,500) |
168,346 |
|
-23% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2022-09-08 |
4 |
OE |
$9.65 |
$207,475 |
D/D |
21,500 |
189,846 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-09-07 |
4 |
AS |
$49.11 |
$491,100 |
D/D |
(10,000) |
406,089 |
|
-18% |
|
| Blum Robert I |
President & CEO |
• • – |
2022-09-07 |
4 |
OE |
$7.96 |
$79,600 |
D/D |
10,000 |
416,089 |
|
- |
|
| Smith Sandford D |
Director |
• • – |
2022-09-02 |
4 |
S |
$53.97 |
$613,585 |
D/D |
(11,369) |
12,170 |
|
21% |
|
| Smith Sandford D |
Director |
• • – |
2022-09-02 |
4 |
OE |
$10.68 |
$269,022 |
D/D |
11,369 |
23,539 |
|
- |
|
| Costa Santo J |
Director |
• • – |
2022-09-01 |
4 |
AS |
$52.79 |
$791,850 |
D/D |
(15,000) |
10,000 |
|
-21% |
|
| Costa Santo J |
Director |
• • – |
2022-09-01 |
4 |
OE |
$9.45 |
$154,050 |
D/D |
15,000 |
25,000 |
|
- |
|
710 Records found
|
|
Page 8 of 29 |
|
|
1.92 (3%) 
